Search

Your search keyword '"Coupé, Veerle"' showing total 757 results
Start Over Author "Coupé, Veerle"
757 results on '"Coupé, Veerle"'

52. A scenario‐drafting study to explore potential future implementation pathways of circulating tumor DNA testing in oncology

Author

Kramer, Astrid, primary, Rubio‐Alarcón, Carmen, additional, van den Broek, Daan, additional, Vessies, Daan C. L., additional, van `t Erve, Iris, additional, Meijer, Gerrit A., additional, Vink, Geraldine R., additional, Schuuring, Ed, additional, Fijneman, Remond J.A., additional, Coupé, Veerle M.H., additional, and Retèl, Valesca P., additional

Published
2023
Full Text
View/download PDF

54. TABLE 3 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., primary, Lemmens, Margriet, primary, Delis-van Diemen, Pien M., primary, Klotz, Dagmar, primary, Leon, Leticia G., primary, Lakbir, Soufyan, primary, de Wit, Meike, primary, Fijneman, Remond J.A., primary, van Leerdam, Monique E., primary, Dekker, Evelien, primary, Spaander, Manon C.W., primary, Meijer, Gerrit A., primary, Løberg, Magnus, primary, Coupé, Veerle M.H., primary, Kalager, Mette, primary, and Carvalho, Beatriz, primary

Published
2023
Full Text
View/download PDF

55. TABLE 4 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., primary, Lemmens, Margriet, primary, Delis-van Diemen, Pien M., primary, Klotz, Dagmar, primary, Leon, Leticia G., primary, Lakbir, Soufyan, primary, de Wit, Meike, primary, Fijneman, Remond J.A., primary, van Leerdam, Monique E., primary, Dekker, Evelien, primary, Spaander, Manon C.W., primary, Meijer, Gerrit A., primary, Løberg, Magnus, primary, Coupé, Veerle M.H., primary, Kalager, Mette, primary, and Carvalho, Beatriz, primary

Published
2023
Full Text
View/download PDF

56. FIGURE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., primary, Lemmens, Margriet, primary, Delis-van Diemen, Pien M., primary, Klotz, Dagmar, primary, Leon, Leticia G., primary, Lakbir, Soufyan, primary, de Wit, Meike, primary, Fijneman, Remond J.A., primary, van Leerdam, Monique E., primary, Dekker, Evelien, primary, Spaander, Manon C.W., primary, Meijer, Gerrit A., primary, Løberg, Magnus, primary, Coupé, Veerle M.H., primary, Kalager, Mette, primary, and Carvalho, Beatriz, primary

Published
2023
Full Text
View/download PDF

57. Supplementary Figure 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., primary, Lemmens, Margriet, primary, Delis-van Diemen, Pien M., primary, Klotz, Dagmar, primary, Leon, Leticia G., primary, Lakbir, Soufyan, primary, de Wit, Meike, primary, Fijneman, Remond J.A., primary, van Leerdam, Monique E., primary, Dekker, Evelien, primary, Spaander, Manon C.W., primary, Meijer, Gerrit A., primary, Løberg, Magnus, primary, Coupé, Veerle M.H., primary, Kalager, Mette, primary, and Carvalho, Beatriz, primary

Published
2023
Full Text
View/download PDF

58. TABLE 7 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., primary, Lemmens, Margriet, primary, Delis-van Diemen, Pien M., primary, Klotz, Dagmar, primary, Leon, Leticia G., primary, Lakbir, Soufyan, primary, de Wit, Meike, primary, Fijneman, Remond J.A., primary, van Leerdam, Monique E., primary, Dekker, Evelien, primary, Spaander, Manon C.W., primary, Meijer, Gerrit A., primary, Løberg, Magnus, primary, Coupé, Veerle M.H., primary, Kalager, Mette, primary, and Carvalho, Beatriz, primary

Published
2023
Full Text
View/download PDF

59. Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., additional, Lemmens, Margriet, additional, Delis-van Diemen, Pien M., additional, Klotz, Dagmar, additional, Leon, Leticia G., additional, Lakbir, Soufyan, additional, de Wit, Meike, additional, Fijneman, Remond J.A., additional, van Leerdam, Monique E., additional, Dekker, Evelien, additional, Spaander, Manon C.W., additional, Meijer, Gerrit A., additional, Løberg, Magnus, additional, Coupé, Veerle M.H., additional, Kalager, Mette, additional, and Carvalho, Beatriz, additional

Published
2023
Full Text
View/download PDF

60. TABLE 5 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., primary, Lemmens, Margriet, primary, Delis-van Diemen, Pien M., primary, Klotz, Dagmar, primary, Leon, Leticia G., primary, Lakbir, Soufyan, primary, de Wit, Meike, primary, Fijneman, Remond J.A., primary, van Leerdam, Monique E., primary, Dekker, Evelien, primary, Spaander, Manon C.W., primary, Meijer, Gerrit A., primary, Løberg, Magnus, primary, Coupé, Veerle M.H., primary, Kalager, Mette, primary, and Carvalho, Beatriz, primary

Published
2023
Full Text
View/download PDF

61. Supplementary Figure 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., primary, Lemmens, Margriet, primary, Delis-van Diemen, Pien M., primary, Klotz, Dagmar, primary, Leon, Leticia G., primary, Lakbir, Soufyan, primary, de Wit, Meike, primary, Fijneman, Remond J.A., primary, van Leerdam, Monique E., primary, Dekker, Evelien, primary, Spaander, Manon C.W., primary, Meijer, Gerrit A., primary, Løberg, Magnus, primary, Coupé, Veerle M.H., primary, Kalager, Mette, primary, and Carvalho, Beatriz, primary

Published
2023
Full Text
View/download PDF

62. TABLE 6 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., primary, Lemmens, Margriet, primary, Delis-van Diemen, Pien M., primary, Klotz, Dagmar, primary, Leon, Leticia G., primary, Lakbir, Soufyan, primary, de Wit, Meike, primary, Fijneman, Remond J.A., primary, van Leerdam, Monique E., primary, Dekker, Evelien, primary, Spaander, Manon C.W., primary, Meijer, Gerrit A., primary, Løberg, Magnus, primary, Coupé, Veerle M.H., primary, Kalager, Mette, primary, and Carvalho, Beatriz, primary

Published
2023
Full Text
View/download PDF

63. Data from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., primary, Lemmens, Margriet, primary, Delis-van Diemen, Pien M., primary, Klotz, Dagmar, primary, Leon, Leticia G., primary, Lakbir, Soufyan, primary, de Wit, Meike, primary, Fijneman, Remond J.A., primary, van Leerdam, Monique E., primary, Dekker, Evelien, primary, Spaander, Manon C.W., primary, Meijer, Gerrit A., primary, Løberg, Magnus, primary, Coupé, Veerle M.H., primary, Kalager, Mette, primary, and Carvalho, Beatriz, primary

Published
2023
Full Text
View/download PDF

64. FIGURE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., primary, Lemmens, Margriet, primary, Delis-van Diemen, Pien M., primary, Klotz, Dagmar, primary, Leon, Leticia G., primary, Lakbir, Soufyan, primary, de Wit, Meike, primary, Fijneman, Remond J.A., primary, van Leerdam, Monique E., primary, Dekker, Evelien, primary, Spaander, Manon C.W., primary, Meijer, Gerrit A., primary, Løberg, Magnus, primary, Coupé, Veerle M.H., primary, Kalager, Mette, primary, and Carvalho, Beatriz, primary

Published
2023
Full Text
View/download PDF

65. TABLE 2 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., primary, Lemmens, Margriet, primary, Delis-van Diemen, Pien M., primary, Klotz, Dagmar, primary, Leon, Leticia G., primary, Lakbir, Soufyan, primary, de Wit, Meike, primary, Fijneman, Remond J.A., primary, van Leerdam, Monique E., primary, Dekker, Evelien, primary, Spaander, Manon C.W., primary, Meijer, Gerrit A., primary, Løberg, Magnus, primary, Coupé, Veerle M.H., primary, Kalager, Mette, primary, and Carvalho, Beatriz, primary

Published
2023
Full Text
View/download PDF

66. TABLE 1 from Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas: A Nested Case–Control Study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., primary, Lemmens, Margriet, primary, Delis-van Diemen, Pien M., primary, Klotz, Dagmar, primary, Leon, Leticia G., primary, Lakbir, Soufyan, primary, de Wit, Meike, primary, Fijneman, Remond J.A., primary, van Leerdam, Monique E., primary, Dekker, Evelien, primary, Spaander, Manon C.W., primary, Meijer, Gerrit A., primary, Løberg, Magnus, primary, Coupé, Veerle M.H., primary, Kalager, Mette, primary, and Carvalho, Beatriz, primary

Published
2023
Full Text
View/download PDF

70. An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles

Author

Bresalier, Robert S, primary, Senore, Carlo, additional, Young, Graeme P, additional, Allison, James, additional, Benamouzig, Robert, additional, Benton, Sally, additional, Bossuyt, Patrick M M, additional, Caro, Luis, additional, Carvalho, Beatriz, additional, Chiu, Han-Mo, additional, Coupé, Veerle M H, additional, de Klaver, Willemijn, additional, de Klerk, Clasine Maria, additional, Dekker, Evelien, additional, Dolwani, Sunil, additional, Fraser, Callum G, additional, Grady, William, additional, Guittet, Lydia, additional, Gupta, Samir, additional, Halloran, Stephen P, additional, Haug, Ulrike, additional, Hoff, Geir, additional, Itzkowitz, Steven, additional, Kortlever, Tim, additional, Koulaouzidis, Anastasios, additional, Ladabaum, Uri, additional, Lauby-Secretan, Beatrice, additional, Leja, Mārcis, additional, Levin, Bernard, additional, Levin, Theodore Robert, additional, Macrae, Finlay, additional, Meijer, Gerrit A, additional, Melson, Joshua, additional, O'Morain, Colm, additional, Parry, Susan, additional, Rabeneck, Linda, additional, Ransohoff, David F, additional, Sáenz, Roque, additional, Saito, Hiroshi, additional, Sanduleanu-Dascalescu, Silvia, additional, Schoen, Robert E, additional, Selby, Kevin, additional, Singh, Harminder, additional, Steele, Robert J C, additional, Sung, Joseph J Y, additional, Symonds, Erin Leigh, additional, and Winawer, Sidney J, additional

Published
2023
Full Text
View/download PDF

78. Abstract 3358: PLCRC-PROVENC3: assessing the prognostic value of post-surgery liquid biopsy cell-free circulating tumor DNA in stage III colon cancer patients

Author

Rubio-Alarcon, Carmen, primary, Ketelaars, Steven L., additional, Franken, Ingrid A., additional, van Nassau, Sietske C., additional, van der Kruijssen, Dave E., additional, Schraa, Suzanna J., additional, Linders, Theodora C., additional, Diemen, Pien Delis-van, additional, Alkemade, Maartje, additional, Bolijn, Anne, additional, Tijssen, Marianne, additional, Lemmens, Margriet, additional, van Dongen, Miranda, additional, Lanfermeijer, Mirthe, additional, Broeks, Annegien, additional, Meiqari, Lana, additional, Bosch, Linda J., additional, Velculescu, Victor E., additional, Greer, Amy, additional, Angiuoli, Samuel V., additional, Georgiadis, Andrew, additional, Riley, David, additional, White, James R., additional, Greco, Christopher, additional, Cox, Liam, additional, Broek, Daan van den, additional, Punt, Cornelis J., additional, Coupé, Veerle M., additional, Koopman, Miriam, additional, Roodhart, Jeanine, additional, Meijer, Gerrit A., additional, Sausen, Mark, additional, Vink, Geraldine R., additional, and Fijneman, Remond J., additional

Published
2023
Full Text
View/download PDF

79. Supplementary Table 2 from Evaluation of Cancer-Associated DNA Copy Number Events in Colorectal (Advanced) Adenomas

Author

Carvalho, Beatriz, primary, Diosdado, Begoña, primary, Terhaar Sive Droste, Jochim S., primary, Bolijn, Anne S., primary, Komor, Malgorzata A., primary, de Wit, Meike, primary, Bosch, Linda J.W., primary, van Burink, Myrthe, primary, Dekker, Evelien, primary, Kuipers, Ernst J., primary, Coupé, Veerle M.H., primary, van Grieken, Nicole C.T., primary, Fijneman, Remond J.A., primary, and Meijer, Gerrit A., primary

Published
2023
Full Text
View/download PDF

80. Supplementary Figures 1-4, Tables 1-5 from DNA Methylation of Phosphatase and Actin Regulator 3 Detects Colorectal Cancer in Stool and Complements FIT

Author

Bosch, Linda J.W., primary, Oort, Frank A., primary, Neerincx, Maarten, primary, Khalid-de Bakker, Carolina A.J., primary, sive Droste, Jochim S. Terhaar, primary, Melotte, Veerle, primary, Jonkers, Daisy M.A.E., primary, Masclee, Ad A.M., primary, Mongera, Sandra, primary, Grooteclaes, Madeleine, primary, Louwagie, Joost, primary, van Criekinge, Wim, primary, Coupé, Veerle M.H., primary, Mulder, Chris J., primary, van Engeland, Manon, primary, Carvalho, Beatriz, primary, and Meijer, Gerrit A., primary

Published
2023
Full Text
View/download PDF

81. Supplementary Methods from DNA Methylation of Phosphatase and Actin Regulator 3 Detects Colorectal Cancer in Stool and Complements FIT

Author

Bosch, Linda J.W., primary, Oort, Frank A., primary, Neerincx, Maarten, primary, Khalid-de Bakker, Carolina A.J., primary, sive Droste, Jochim S. Terhaar, primary, Melotte, Veerle, primary, Jonkers, Daisy M.A.E., primary, Masclee, Ad A.M., primary, Mongera, Sandra, primary, Grooteclaes, Madeleine, primary, Louwagie, Joost, primary, van Criekinge, Wim, primary, Coupé, Veerle M.H., primary, Mulder, Chris J., primary, van Engeland, Manon, primary, Carvalho, Beatriz, primary, and Meijer, Gerrit A., primary

Published
2023
Full Text
View/download PDF

82. Data from DNA Methylation of Phosphatase and Actin Regulator 3 Detects Colorectal Cancer in Stool and Complements FIT

Author

Bosch, Linda J.W., primary, Oort, Frank A., primary, Neerincx, Maarten, primary, Khalid-de Bakker, Carolina A.J., primary, sive Droste, Jochim S. Terhaar, primary, Melotte, Veerle, primary, Jonkers, Daisy M.A.E., primary, Masclee, Ad A.M., primary, Mongera, Sandra, primary, Grooteclaes, Madeleine, primary, Louwagie, Joost, primary, van Criekinge, Wim, primary, Coupé, Veerle M.H., primary, Mulder, Chris J., primary, van Engeland, Manon, primary, Carvalho, Beatriz, primary, and Meijer, Gerrit A., primary

Published
2023
Full Text
View/download PDF

83. Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands

Author

Mfumbilwa, Zakile A, Wilschut, Janneke A, Simons, Martijn J H G, Ramaekers, Bram, Joore, Manuela, Retèl, Valesca, der Welle, Christine M Cramer-van, Schramel, Franz M N H, van de Garde, Ewoudt M W, Coupé, Veerle M H, Mfumbilwa, Zakile A, Wilschut, Janneke A, Simons, Martijn J H G, Ramaekers, Bram, Joore, Manuela, Retèl, Valesca, der Welle, Christine M Cramer-van, Schramel, Franz M N H, van de Garde, Ewoudt M W, and Coupé, Veerle M H

Abstract

Recent discoveries in molecular diagnostics and drug treatments have improved the treatment of patients with advanced (inoperable) non-squamous non-small cell lung cancer (NSCLC) from solely platinum-based chemotherapy to more personalized treatment, including targeted therapies and immunotherapies. However, these improvements come at considerable costs, highlighting the need to assess their cost-effectiveness in order to optimize lung cancer care. Traditionally, cost-effectiveness models for the evaluation of new lung cancer treatments were based on the findings of the randomized control trials (RCTs). However, the strict RCT inclusion criteria make RCT patients not representative of patients in the real-world. Patients in RCTs have a better prognosis than patients in a real-world setting. Therefore, in this study, we developed and validated a diagnosis-treatment decision model for patients with advanced (inoperable) non-squamous NSCLC based on real-world data in the Netherlands. The model is a patient-level microsimulation model implemented as discrete event simulation with five health events. Patients are simulated from diagnosis to death, including at most three treatment lines. The base-model (non-personalized strategy) was populated using real-world data of patients treated with platinum-based chemotherapy between 2008 and 2014 in one of six Dutch teaching hospitals. To simulate personalized care, molecular tumor characteristics were incorporated in the model based on the literature. The impact of novel targeted treatments and immunotherapies was included based on published RCTs. To validate the model, we compared survival under a personalized treatment strategy with observed real-world survival. This model can be used for health-care evaluation of personalized treatment for patients with advanced (inoperable) NSCLC in the Netherlands.

Published
2023

84. Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Mfumbilwa, Zakile A, Wilschut, Janneke A, Simons, Martijn J H G, Ramaekers, Bram, Joore, Manuela, Retèl, Valesca, der Welle, Christine M Cramer-van, Schramel, Franz M N H, van de Garde, Ewoudt M W, Coupé, Veerle M H, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Mfumbilwa, Zakile A, Wilschut, Janneke A, Simons, Martijn J H G, Ramaekers, Bram, Joore, Manuela, Retèl, Valesca, der Welle, Christine M Cramer-van, Schramel, Franz M N H, van de Garde, Ewoudt M W, and Coupé, Veerle M H

Published
2023

85. Towards patient-led follow-up after curative surgical resection of stage I, II and III colorectal cancer (DISTANCE-trial):a study protocol for a stepped-wedge cluster-randomised trial

Author

Swartjes, Hidde, Qaderi, Seyed M., Teerenstra, Steven, Custers, Jose A.E., Elferink, Marloes A.G., van Wely, Bob J., Burger, Jacobus W.A., van Grevenstein, Wilhelmina M.U., van Duijvendijk, Peter, Verdaasdonk, Emiel G.G., de Roos, Marnix A.J., Coupé, Veerle M.H., Vink, Geraldine R., Verhoef, Cornelis, de Wilt, Johannes H.W., Swartjes, Hidde, Qaderi, Seyed M., Teerenstra, Steven, Custers, Jose A.E., Elferink, Marloes A.G., van Wely, Bob J., Burger, Jacobus W.A., van Grevenstein, Wilhelmina M.U., van Duijvendijk, Peter, Verdaasdonk, Emiel G.G., de Roos, Marnix A.J., Coupé, Veerle M.H., Vink, Geraldine R., Verhoef, Cornelis, and de Wilt, Johannes H.W.

Abstract

Background: Colorectal cancer (CRC) is among the most frequently diagnosed cancers. Approximately 20–30% of stage I-III CRC patients develop a recurrent tumour or metastases after curative surgical resection. Post-operative follow-up is indicated for the first five years after curative surgical resection. As intensified follow-up after curative surgical resection has shown no effect on survival, patient organisations and policy makers have advocated for a more patient-centred approach to follow-up. The objective of this study is to successfully implement patient-led, home-based follow-up (PHFU) in six hospitals in The Netherlands, with as ultimate aim to come to a recommendation for a patient-centred follow-up schedule for stage I-III CRC patients treated with surgical resection with curative intent. Methods: This study is designed as a stepped-wedge cluster-randomised trial (SW-CRT) in six participating centres. During the trial, three centres will implement PHFU after six months; the other three centres will implement PHFU after 12 months of inclusion in the control group. Eligible patients are those with pT2-4N0M0 or pT1-4N1-2M0 CRC, who are 18 years or older and have been free of disease for 12 months after curative surgical resection. The studied intervention is PHFU, starting 12 months after curative resection. The in-hospital, standard-of-care follow-up currently implemented in the participating centres functions as the comparator. The proportion of patients who had contact with the hospital regarding CRC follow-up between 12–24 months after curative surgical resection is the primary endpoint of this study. Quality of life, fear of cancer recurrence, patient satisfaction, cost-effectiveness and survival are the secondary endpoints. Discussion: The results of this study will provide evidence on whether nationwide implementation of PHFU for CRC in The Netherlands will be successful in reducing contact between patient and health care provider. Comparison of P

Published
2023

86. Towards patient-led follow-up after curative surgical resection of stage I, II and III colorectal cancer (DISTANCE-trial): a study protocol for a stepped-wedge cluster-randomised trial

Author

MS CGO, Cancer, Medisch Oncologische Disciplines, Onderzoek Medische Oncologie, Swartjes, Hidde, Qaderi, Seyed M., Teerenstra, Steven, Custers, Jose A.E., Elferink, Marloes A.G., van Wely, Bob J., Burger, Jacobus W.A., van Grevenstein, Wilhelmina M.U., van Duijvendijk, Peter, Verdaasdonk, Emiel G.G., de Roos, Marnix A.J., Coupé, Veerle M.H., Vink, Geraldine R., Verhoef, Cornelis, de Wilt, Johannes H.W., MS CGO, Cancer, Medisch Oncologische Disciplines, Onderzoek Medische Oncologie, Swartjes, Hidde, Qaderi, Seyed M., Teerenstra, Steven, Custers, Jose A.E., Elferink, Marloes A.G., van Wely, Bob J., Burger, Jacobus W.A., van Grevenstein, Wilhelmina M.U., van Duijvendijk, Peter, Verdaasdonk, Emiel G.G., de Roos, Marnix A.J., Coupé, Veerle M.H., Vink, Geraldine R., Verhoef, Cornelis, and de Wilt, Johannes H.W.

Published
2023

87. Risk Prediction of Metachronous Colorectal Cancer from Molecular Features of Adenomas:A Nested Case-Control Study

Author

Jodal, Henriette C, Akwiwu, Eddymurphy U, Lemmens, Margriet, Delis-van Diemen, Pien M, Klotz, Dagmar, Leon, Leticia G, Lakbir, Soufyan, de Wit, Meike, Fijneman, Remond J A, van Leerdam, Monique E, Dekker, Evelien, Spaander, Manon C W, Meijer, Gerrit A, Løberg, Magnus, Coupé, Veerle M H, Kalager, Mette, Carvalho, Beatriz, Jodal, Henriette C, Akwiwu, Eddymurphy U, Lemmens, Margriet, Delis-van Diemen, Pien M, Klotz, Dagmar, Leon, Leticia G, Lakbir, Soufyan, de Wit, Meike, Fijneman, Remond J A, van Leerdam, Monique E, Dekker, Evelien, Spaander, Manon C W, Meijer, Gerrit A, Løberg, Magnus, Coupé, Veerle M H, Kalager, Mette, and Carvalho, Beatriz

Abstract

Current morphologic features defining advanced adenomas (size ≥10 mm, high-grade dysplasia or ≥25% villous component) cannot optimally distinguish individuals at high risk or low risk of metachronous colorectal cancer (me-CRC), which may result in suboptimal surveillance. Certain DNA copy-number alterations (CNAs) are associated with adenoma-tocarcinoma progression. We aimed to evaluate whether these molecular features can better predict an individual's risk of me-CRC than the morphologic advanced adenoma features. In this nested case-control study, 529 individuals with a single adenoma at first colonoscopy were selected from a Norwegian adenoma cohort. DNA copy-number profileswere determined, by low-coveragewhole-genome sequencing. Prevalence of CNAs in advanced and non-advanced adenomas and its association (OR) with me-CRC was assessed. For the latter, cases (withme-CRC) were matched to controls (withoutme-CRC) on follow-up, age and sex. CNAs associated with adenoma-to-carcinoma progression were observed in 85/267 (32%) of advanced adenomas and in 27/262 (10%) of nonadvanced adenomas.me-CRC was statistically significantly associated, also after adjustment for other variables, with age at baseline [OR, 1.14; 95% confidence interval CI), 1.03-1.26; P = 0.012], advanced adenomas (OR, 2.46; 95% CI, 1.50-4.01; P < 0.001) and with the presence of ≥3 DNA copy-number losses (OR, 1.90; 95% CI. 1.02-3.54; P = 0.043). Molecularly-defined high-risk adenomas were associated with me-CRC, but the association of advanced adenoma with me-CRC was stronger.

Published
2023

90. Prevalence of adjustment disorder among cancer patients, and the reach, effectiveness, cost-utility and budget impact of tailored psychological treatment: study protocol of a randomized controlled trial

Author

van Beek, Florie E., Wijnhoven, Lonneke M. A., Jansen, Femke, Custers, José A. E., Aukema, Eline J., Coupé, Veerle M. H., Cuijpers, Pim, van der Lee, Marije L., Lissenberg-Witte, Birgit I., Wijnen, Ben, Prins, Judith B., and Verdonck-de Leeuw, Irma M.

Published
2019
Full Text
View/download PDF

91. Efficacy and cost-utility of the eHealth application ‘Oncokompas’, supporting patients with incurable cancer in finding optimal palliative care, tailored to their quality of life and personal preferences: a study protocol of a randomized controlled trial

Author

Schuit, Anouk S., Holtmaat, Karen, Hooghiemstra, Nienke, Jansen, Femke, Lissenberg-Witte, Birgit I., Coupé, Veerle M. H., van Linde, Myra E., Becker-Commissaris, Annemarie, Reijneveld, Jaap C., Zijlstra, Josée M., Sommeijer, Dirkje W., Eerenstein, Simone E. J., and Verdonck-de Leeuw, Irma M.

Published
2019
Full Text
View/download PDF

97. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study

Author

van Wifferen, Francine, de Jonge, Lucie, Worthington, Joachim, Greuter, Marjolein J.E., Lew, Jie Bin, Nadeau, Claude, van den Puttelaar, Rosita, Feletto, Eleonora, Yong, Jean H.E., Lansdorp-Vogelaar, Iris, Canfell, Karen, Coupé, Veerle M.H., Hahn, A., Njor, S., Public Health, Gastroenterology and Hepatology, CCA - Cancer Treatment and Quality of Life, CCA - Imaging and biomarkers, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Epidemiology and Data Science, APH - Methodology, APH - Quality of Care, and CCA - Cancer Treatment and quality of life

Subjects
Health Policy, Public Health, Environmental and Occupational Health, COVID-19, Colonoscopy, Colorectal Neoplasms/diagnosis, FIT, Colorectal cancer, Coronavirus, Feces, SDG 3 - Good Health and Well-being, Occult Blood, Screening, Humans, Mass Screening, Colorectal Neoplasms, Pandemics, Early Detection of Cancer
Abstract

Objectives Colorectal cancer (CRC) screening with a faecal immunochemical test (FIT) has been disrupted in many countries during the COVID-19 pandemic. Performing catch-up of missed screens while maintaining regular screening services requires additional colonoscopy capacity that may not be available. This study aimed to compare strategies that clear the screening backlog using limited colonoscopy resources. Methods A range of strategies were simulated using four country-specific CRC natural-history models: Adenoma and Serrated pathway to Colorectal CAncer (ASCCA) and MIcrosimulation SCreening ANalysis for CRC (MISCAN-Colon) (both in the Netherlands), Policy1-Bowel (Australia) and OncoSim (Canada). Strategies assumed a 3-month screening disruption with varying recovery period lengths (6, 12, and 24 months) and varying FIT thresholds for diagnostic colonoscopy. Increasing the FIT threshold reduces the number of referrals to diagnostic colonoscopy. Outcomes for each strategy were colonoscopy demand and excess CRC-related deaths due to the disruption. Results Performing catch-up using the regular FIT threshold in 6, 12 and 24 months could prevent most excess CRC-related deaths, but required 50%, 25% and 12.5% additional colonoscopy demand, respectively. Without exceeding usual colonoscopy demand, up to 60% of excess CRC-related deaths can be prevented by increasing the FIT threshold for 12 or 24 months. Large increases in FIT threshold could lead to additional deaths rather than preventing them. Conclusions Clearing the screening backlog in 24 months could avert most excess CRC-related deaths due to a 3-month disruption but would require a small increase in colonoscopy demand. Increasing the FIT threshold slightly over 24 months could ease the pressure on colonoscopy resources.

Published
2021
Full Text
View/download PDF

98. Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation

Author

Puijk, Robbert, Ahmed, Muneeb, Adam, Andreas, Arai, Yasuaki, Arellano, Ronald, de Baère, Thierry, Bale, Reto, Bellera, Carine, Binkert, Christoph, Brace, Christopher, Breen, David, Brountzos, Elias, Callstrom, Matthew, Carrafiello, Gianpaolo, Chapiro, Julius, de Cobelli, Francesco, Coupé, Veerle, Crocetti, Laura, Denys, Alban, Dupuy, Damian, Erinjeri, Joseph, Filippiadis, Dimitris, Gangi, Afshin, Gervais, Debra, Gillams, Alice, Greene, Tissy, Guiu, Boris, Helmberger, Thomas, Iezzi, Roberto, Kang, Tae Wook, Kelekis, Alexis, Kim, Hyun, Kröncke, Thomas, Kwan, Sharon, Lee, Min Woo, Lee, Fred, Lee, Edward, Liang, Ping, Lissenberg-Witte, Birgit, Lu, David, Madoff, David, Mauri, Giovanni, Meloni, Maria Franca, Morgan, Robert, Nadolski, Gregory, Narayanan, Govindarajan, Newton, Isabel, Nikolic, Boris, Orsi, Franco, Pereira, Philippe, Pua, Uei, Rhim, Hyunchul, Ricke, Jens, Rilling, William, Salem, Riad, Scheffer, Hester, Sofocleous, Constantinos, Solbiati, Luigi, Solomon, Stephen, Soulen, Michael, Sze, Daniel, Uberoi, Raman, Vogl, Thomas, Wang, David, Wood, Bradford, Goldberg, S Nahum, Meijerink, Martijn, Goldberg, S. Nahum, Amsterdam UMC - Amsterdam University Medical Center, Harvard Medical School [Boston] (HMS), Guy's and St Thomas' Hospital [London], National Cancer Center Hospital (NCCJ), Department of radiology (Massachusetts General Hospital), Massachusetts General Hospital [Boston], Institut Gustave Roussy (IGR), Imagerie thérapeutique (radiologie interventionnelle), Département d'imagerie médicale [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), Institut Bergonié [Bordeaux], UNICANCER, Kantonsspital Winterthur (KSW), University of Wisconsin School of Medicine and Public Health, University Hospital Southampton NHS Foundation Trust, National and Kapodistrian University of Athens (NKUA), Mayo Clinic [Rochester], Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Yale University [New Haven], IRCCS Ospedale San Raffaele [Milan, Italy], Vrije Universiteit Medical Centre (VUMC), Vrije Universiteit Amsterdam [Amsterdam] (VU), University of Pisa - Università di Pisa, Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Warren Alpert Medical School of Brown University, Memorial Sloan Kettering Cancer Center (MSKCC), L'Institut hospitalo-universitaire de Strasbourg (IHU Strasbourg), Institut National de Recherche en Informatique et en Automatique (Inria)-l'Institut de Recherche contre les Cancers de l'Appareil Digestif (IRCAD)-Les Hôpitaux Universitaires de Strasbourg (HUS)-La Fédération des Crédits Mutuels Centre Est (FCMCE)-L'Association pour la Recherche contre le Cancer (ARC)-La société Karl STORZ, The London Clinic cancer, Society of Interventional Oncology (SIO), Service de radiologie et d'Imagerie médicale diagnostique et thérapeutique (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein (UKSH), and Kiel University

Subjects
Ablation Techniques, medicine.medical_specialty, Consensus, [SDV]Life Sciences [q-bio], MESH: Societies, Medical, MEDLINE, Outcome (game theory), Session (web analytics), Quality of life (healthcare), Humans, Neoplasms, Reproducibility of Results, Societies, Medical, Medical, medicine, MESH: Neoplasms, Radiology, Nuclear Medicine and imaging, Medical physics, ddc:610, MESH: Consensus, License, MESH: Humans, Health economics, business.industry, MESH: Ablation Techniques, Opinion leadership, MESH: Reproducibility of Results, Clinical trial, business, Societies
Abstract

International audience; There is currently no consensus regarding preferred clinical outcome measures following image-guided tumor ablation or clear definitions of oncologic end points. This consensus document proposes standardized definitions for a broad range of oncologic outcome measures with recommendations on how to uniformly document, analyze, and report outcomes. The initiative was coordinated by the Society of Interventional Oncology in collaboration with the Definition for the Assessment of Time-to-Event End Points in Cancer Trials, or DATECAN, group. According to predefined criteria, based on experience with clinical trials, an international panel of 62 experts convened. Recommendations were developed using the validated three-step modified Delphi consensus method. Consensus was reached on when to assess outcomes per patient, per session, or per tumor; on starting and ending time and survival time definitions; and on time-to-event end points. Although no consensus was reached on the preferred classification system to report complications, quality of life, and health economics issues, the panel did agree on using the most recent version of a validated patient-reported outcome questionnaire. This article provides a framework of key opinion leader recommendations with the intent to facilitate a clear interpretation of results and standardize worldwide communication. Widespread adoption will improve reproducibility, allow for accurate comparisons, and avoid misinterpretations in the field of interventional oncology research. Published under a CC BY 4.0 license. Online supplemental material is available for this article. See also the editorial by Liddell in this issue.

Published
2021
Full Text
View/download PDF

99. PP47 Modelling Non-small Cell Lung Cancer Treatment: Predicted and Observed Impact Of Immunotherapy In The Netherlands

Author

Mfumbilwa, Zakile A, primary, Wilschut, Janneke A, additional, Simons, Martijn J.H.G, additional, Ramaekers, Bram, additional, Joore, Manuela, additional, Retel, Valesca, additional, Cramer-van der Welle, Christine M, additional, Schramel, Franz M.N.H, additional, van de Garde, Ewoudt M.W, additional, and Coupé, Veerle M.H, additional

Published
2022
Full Text
View/download PDF

100. Abstract A004: Molecular adenoma features to predict metachronous colorectal cancer risk: A nested-case control study

Author

Jodal, Henriette C., primary, Akwiwu, Eddymurphy U., additional, Leon, Leticia G., additional, Lemmens, Margriet, additional, Delis-van Diemen, Pien, additional, Klotz, Dagmar, additional, de Wit, Meike, additional, Fijneman, Remond, additional, van Leerdam, Monique, additional, Dekker, Evelien, additional, Spaander, Manon C. W., additional, Meijer, Gerrit A., additional, Bretthauer, Michael, additional, Løberg, Magnus, additional, Coupé, Veerle M. H., additional, Kalager, Mette, additional, and Carvalho, Beatriz, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results